Letters to the editor [1]

Journal of Trauma - Injury, Infection and Critical Care

Volumn 60, Issue 1, 2006, Pages 242-243

  Webert, Kathryn E ^a   Blajchman, Morris A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD TRANSFUSION; BLUNT TRAUMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; ERYTHROCYTE TRANSFUSION; FUNDING; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT SELECTION; PENETRATING TRAUMA; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

EID: 33646099404     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000196343.14187.fd     Document Type: Letter

References (5)

1. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized, placebo-controlled, double-blind clinical trials. J Trauma.2005;59:8-18.
2. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157-163.
3. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality. BMJ. 2003;326:1167-1170.
4. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2:e138.
5. Horton R. The dawn of McScience. New York Rev Books. 2004;51:7-9.